CTLA4 and neoplasm: More interestingly, anti-PD-L1, albeit ineffective in combination with IL-15SA/IL-15RαSu-Fc in this tumor model, appeared to further improve survival when administered in conjunction with both IL-15SA/IL-15RαSu-Fc and anti-CTLA-4 (Figure 8C).